tropisetron Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin receptor antagonists (5-HT3) 2775 89565-68-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tropisetron
  • navoban
  • tropisetron hydrochloride
  • tropisetron HCl
An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.
  • Molecular weight: 284.36
  • Formula: C17H20N2O2
  • CLOGP: 2.88
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 45.33
  • ALOGS: -2.33
  • ROTB: 3

Drug dosage:

DoseUnitRoute
5 mg O
5 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 11 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.25 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 66 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 9.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 26 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1992 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone marrow failure 105.26 35.42 36 1268 30079 53317683
White blood cell count decreased 51.48 35.42 34 1270 124441 53223321
Neutrophil count decreased 40.46 35.42 21 1283 49077 53298685
Tongue neoplasm malignant stage unspecified 39.67 35.42 8 1296 842 53346920
Myelosuppression 35.80 35.42 13 1291 12815 53334947

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone marrow failure 42.43 33.37 20 977 30384 32482145
Myelosuppression 41.49 33.37 15 982 11661 32500868
Platelet count decreased 38.21 33.37 30 967 114561 32397968

Pharmacologic Action:

SourceCodeDescription
ATC A04AA03 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Serotonin (5HT3) antagonists
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D058831 Serotonin 5-HT3 Receptor Antagonists
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
CHEBI has role CHEBI:36335 trypanosomicidal agents
CHEBI has role CHEBI:47958 muscarinic agonists
CHEBI has role CHEBI:48279 5-hydroxytryptamine antagonists
CHEBI has role CHEBI:50846 Biomodulator
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:67079 antiinflammatory agents
CHEBI has role CHEBI:68494 Type I programmed cell-death inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.91 acidic
pKa2 9.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 3A Ion channel ANTAGONIST Ki 8.80 IUPHAR IUPHAR
Sodium-dependent serotonin transporter Transporter Ki 6.59 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 8.28 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 5.61 DRUG MATRIX
Glycine receptor subunit alpha-1 Ion channel ANTAGONIST Ki 4.10 IUPHAR
Glycine receptor subunit alpha-2 Ion channel ANTAGONIST Ki 4.90 IUPHAR
5-hydroxytryptamine receptor 4 GPCR Ki 6.85 WOMBAT-PK
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 8.16 CHEMBL
Glycine receptor subunit beta Ion channel ANTAGONIST Ki 5.30 IUPHAR
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Ki 4.26 CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 4.57 CHEMBL
5-hydroxytryptamine receptor 3B Ion channel Ki 8.80 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 4.80 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel EC50 8 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 7.20 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 8.16 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel Kd 7.52 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 8.89 CHEMBL
Serotonin 3 receptor (5HT3) Ion channel Ki 8.42 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 6.90 CHEMBL
5-hydroxytryptamine receptor 4 GPCR ANTAGONIST Ki 7.10 IUPHAR

External reference:

IDSource
D02041 KEGG_DRUG
105826-92-4 SECONDARY_CAS_RN
C0063322 UMLSCUI
CHEBI:32269 CHEBI
TKT PDB_CHEM_ID
CHEMBL56564 ChEMBL_ID
DB11699 DRUGBANK_ID
D000077526 MESH_DESCRIPTOR_UI
656665 PUBCHEM_CID
260 IUPHAR_LIGAND_ID
6535 INN_ID
6I819NIK1W UNII
235997 RXNORM
004472 NDDF
004473 NDDF
322201005 SNOMEDCT_US
395917006 SNOMEDCT_US
426339000 SNOMEDCT_US

Pharmaceutical products:

None